Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast NephropathyFrank Bridoux, Bertrand Arnulf, Cécile Vigneau et al.|JAMA|2017Cited by 164
Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trialXavier Leleu, Amine Kasmi, Cyrille Hulin et al.|Nature Medicine|2024Cited by 109
Exome sequencing identifies germline variants in DIS3 in familial multiple myelomaMaroulio Pertesi, Bertrand Joly, Maxime Vallée et al.|Leukemia|2019Cited by 47
Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast NephropathyFrank Bridoux, Bertrand Arnulf, Lionel Karlin et al.|Journal of Clinical Oncology|2020Cited by 47
Treatment of Myeloma Cast Nephropathy (MCN): A Randomized Trial Comparing Intensive Haemodialysis (HD) with High Cut-Off (HCO) or Standard High-Flux Dialyzer in Patients Receiving a Bortezomib-Based Regimen (the MYRE Study, by the Intergroupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT))Frank Bridoux, Jean‐Paul Fermand, Brigitte Pegourié et al.|Blood|2016Cited by 15